378 published test results across 73 vendors · latest: 6 Oct 2026
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | PPeptide Crafters Unverified | 10 | $11.40 | 81 |
| 2 | PParamount Peptides | 9 | $22.50 | 80 |
| 3 | SSkye Peptides | 9 | $13.39 | 79 |
| 4 | PPeptide Sciences | 15 | $28.33 | 79 |
| 5 | HHXNet Unverified | 5 | $1.00 | 77 |
| 6 | BBulk Peptide Supply | 5 | $3.50 | 76 |
| 7 | PPeptide Gurus Unverified | 6 | $5.60 | 75 |
| 8 | TTydes Unverified | 9 | $11.00 | 75 |
| 9 | RRoyal Peptides | 8 | $3.00 | 74 |
| 10 | SShanghai Sigma Audley SSA Unverified | 10 | $1.10 | 74 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Semaglutide is the GLP-1 receptor agonist peptide that started the modern weight-loss era, approved as Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (oral tablets). Because approved versions exist everywhere, its gray-market “research” form sits in the most heavily enforced corner of the peptide market.
It mimics the incretin hormone GLP-1: appetite suppression, slower gastric emptying, improved insulin response. In its pivotal weight-management trial (STEP 1), weekly semaglutide averaged roughly 15% body-weight reduction at 68 weeks.
Pharmacy semaglutide is GMP-manufactured with verified contents. Research-grade vials are unregulated powder whose quality is only as good as the vendor’s published third-party testing. Semaglutide batches appear regularly in failed-label-claim results. Enforcement is aggressive: in Canada, semaglutide’s approved status puts gray-market versions in a worse category at the border (Canada guide).
Working out reconstitution or syringe units? Use the free peptide calculator, then check your batch’s published test result before trusting the label: vials that miss their label claims turn up regularly in Janoshik’s public results database.
Vendor rankings on PeptideCensus are computed only from publicly published third-party lab results; see the vendor index and how scoring works.
Per the approved products’ labeling: gastrointestinal effects dominate (nausea, vomiting, diarrhea, constipation), dose-related and concentrated during escalation.
Yes: a modified 31-amino-acid GLP-1 analog engineered for once-weekly action.
Sold “for research use only,” but with approved versions on the market, unauthorized sales and imports draw the strictest enforcement in this space.
One, two, and three receptors , with successively larger average weight reductions in their separate trials. See the tirzepatide and retatrutide hubs.
Compounding was permitted during official shortages; as shortage status changed, regulators moved against mass compounded versions. The rules keep shifting, so check the current status as of the date you read this.
PeptideCensus aggregates publicly published third-party lab results and links every number to its source. Nothing on this page is medical advice; research compounds are not for human use.